TCRTHealthcare · BiotechnologyTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 28 of 100 as at 8 Oct 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Alaunos Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (99): Smaller than most of the companies we track.
Quality (12): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on TCRT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 16 Aug 2023 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 15 Aug 2023 | Laidlaw & Co. | Downgrade | Hold | — |
| 15 May 2023 | HC Wainwright & Co. | Upgrade | Buy | $1.50 |
| 27 Mar 2023 | Wells Fargo | Assumes | Overweight | $3.00 |
| 4 Oct 2022 | Wells Fargo | Assumes | Overweight | $3.00 |
| 15 July 2022 | Cantor Fitzgerald | Assumes | Overweight | $3.00 |
| 4 May 2022 | Wells Fargo | Upgrade | Overweight | $3.00 |
| 9 Nov 2021 | Raymond James | Maintains | Market Perform | — |
| 10 Aug 2021 | Raymond James | Downgrade | Market Perform | — |
| 7 May 2021 | Raymond James | Maintains | Outperform | — |
| 12 Mar 2021 | Jefferies | Downgrade | Hold | — |
| 1 Mar 2021 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 19 June 2020 | Jefferies | Initiates | Buy | — |
| 11 May 2020 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 Mar 2020 | Cantor Fitzgerald | Initiates | Overweight | — |
| 3 Mar 2020 | Raymond James | Maintains | Outperform | — |
| 4 Apr 2019 | Lake Street | Initiates | Buy | — |
| 1 Apr 2019 | Laidlaw & Co. | Initiates | Buy | — |
| 15 Nov 2018 | Raymond James | Upgrade | Outperform | — |
| 18 June 2018 | JP Morgan | Downgrade | Underweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TCRT appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 9 Oct 2026, Alaunos Therapeutics, Inc. returned −80.3% against +17.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 80% of US stocks
Cheaper than 1% of US stocks
Cheaper than 30% of US stocks
Cheaper than 65% of US stocks
Higher than 1% of US stocks
Higher than 1% of US stocks
Higher than 1% of US stocks
Higher than 30% of US stocks
Higher than 8% of US stocks
Higher than 4% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Alaunos Therapeutics, Inc. has a market value of $2.5M and an enterprise value of $1.8M.
Revenue in the twelve months to 30 June 2026: $3K. The latest quarter shrank 100.0% year on year.
Net income over the same four quarters: −$4.0M, a −133666.7% net margin.
Free cash flow in the twelve months to 30 June 2026: −$2.8M.
Trailing P/E: −0.4×; forward P/E: −1.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Alaunos Therapeutics, Inc. employs 1 people — $3K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Alaunos Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Alaunos Therapeutics announced the pricing of a registered direct offering of common stock and pre-funded warrants, priced at-the-market under Nasdaq rules, to fund working capital and general corporate purposes.
Why it matters — A TCRT watcher would track this capital raise as it affects the company's share count and cash position.
Shares of Alaunos Therapeutics rose sharply in pre-market trading, up around 22%, after a Securities and Exchange Commission filing showed the company approved and adopted its Second Amended and Restated By-Laws, effective immediately. The gain followed the July disclosure of the by-law change.
Why it matters — A TCRT watcher would care because the adoption of the amended by-laws represents a corporate governance change that drew investor attention and drove a notable pre-market share price move.
As at 8 Oct 2026, Alaunos Therapeutics, Inc. ranks 28 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (99 of 100).
No analyst covering Alaunos Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TCRT are extrapolating price history, which says nothing about the business.
Alaunos Therapeutics, Inc. returned -80.3% over the 12 months to 9 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Alaunos Therapeutics Inc. is a biopharmaceutical company focused on developing therapies for cancer and metabolic disease.
The most recent item we track (GlobeNewsWire, 18 Sept 2026): "Alaunos Therapeutics, Inc. Announces Pricing of Registered Direct Offering priced at-the-market under Nasdaq rules". Alaunos Therapeutics announced the pricing of a registered direct offering of common stock and pre-funded warrants, priced at-the-market under Nasdaq rules, to fund working capital and general corporate purposes.
Alaunos Therapeutics Inc. is a biopharmaceutical company focused on developing therapies for cancer and metabolic disease. Its current portfolio includes clinical-stage and preclinical programs centered on engineered T-cell receptor approaches for solid tumors, along with oral small-molecule candidates for obesity and related metabolic disorders. The company’s oncology work is aimed at addressing difficult-to-treat cancers through immune-based technologies such as TCR-T cell therapies and proprietary discovery platforms for identifying tumor-specific targets. In metabolic health, Alaunos Therapeutics Inc. is developing non-incretin oral compounds designed to offer an alternative therapeutic approach for obesity and associated conditions. Headquartered in Fort Lauderdale, Florida, and founded in 2003, Alaunos Therapeutics Inc. operates in the biotechnology sector and primarily supports its business through research and development activities.
CEO Mr. Holger Weis CPA · 1 employees · United States · https://www.alaunos.com
